10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares of US biotech Stealth BioTherapeutics leapt 28% to $8.20 in pre-market trading today, after it announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases with Alexion Pharmaceuticals. 10 October 2019
The US Food and Drug Administration has granted Breakthrough Therapy designation to Ofev (nintedanib), which is currently under FDA review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. 10 October 2019
US biotech firm Ra Pharmaceutical saw its shares roar ahead 103% to $46.14 in pre-market trading today, on the news that it has agreed to a takeover by Belgium’s largest pharma firm UCB. 10 October 2019
Hutchison China MediTech Limited, also known as Chi-Med, has expanded its global collaboration with fellow Chinese firm Innovent Biologics. 10 October 2019
Hong Kong-based Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical (CTFH), taking on previously undruggable targets. 9 October 2019
A new research collaboration between Danish diabetes giant Novo Nordisk and the Cambridge, USA-based firm bluebird bio will see the companies work together on certain in vivo gene editing technologies. 9 October 2019
Collaboration will be crucial to keeping up with growing consumer demand for microbiome support, writes David Evendon-Challis, vice president of innovation at the consumer goods firm, RB, in an Expert View piece. 9 October 2019
The US regulator has finally approved Scenesse (afamelanotide), a subcutaneous implant used to treat the ultra-rare disorder erythropoietic protoporphyria, in which exposure to sunlight causes pain. 9 October 2019
UK-based biotech firm Prokarium says it has received an investment of £4.59 million ($5.6 million) from the Wellcome Trust to fund two clinical trials of its lead program, Entervax, a bivalent vaccine against enteric fever. 9 October 2019
Basel-based drugmaker Novartis has provided a detailed look at the data propelling late stage development of ligelizumab, a possible replacement for the ageing respiratory drug Xolair (omalizumab). 8 October 2019
The growing stable of Flagship Pioneering now has another member, with this one purportedly the world’s first exoneural biology company. 8 October 2019
GlaxoSmithKline today announced a five-year collaboration with California, USA-based biotech Lyell Immunopharma, to develop new technologies to improve cell therapies for cancer patients. 8 October 2019
Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ pharma unit to join Ascletis as chief scientific officer. 8 October 2019
There were two important drug approvals for medicines regulator Health Canada today, the first being US biotech major Amgen’s new humanized anti-sclerostin monoclonal antibody for osteoporosis. 8 October 2019
US biotech major Gilead Sciences yesterday announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA), has been submitted to the Japanese Ministry of Health, Labor and Welfare (MHLW). 8 October 2019
Shares in South Korean biotech Helixmith are up by more than half after the firm announced results for a first-in-class biologic, VM202. 8 October 2019
With its leading ophthalmology drug Lucentis (ranibizumab) nearing the end of its patent exclusivity, there was good news for Swiss pharma giant Novartis with US regulatory approval for its successor. 8 October 2019
US biotech Sarepta Therapeutics lost more than 50% of its market value between mid-July and last week, with an adverse event report and a US Food and Drug Administration (FDA) rejection of Vyondys 53 (golodirsen) contributing to the damage. 7 October 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024